Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

NCT06954480 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Datopotamab Deruxtecan (Dato-DXd)
DRUG: Durvalumab

Sponsor

Queen Mary University of London

Collaborators

[object Object]